Eli Lilly Case Leaves Big Questions For Another Day
While a recent decision rejecting U.S. drugmaker Eli Lilly's CA$500 million ($375 million) claim against Canada over the invalidation of its patents demonstrates a properly functioning investor-state dispute settlement system, the...To view the full article, register now.
Already a subscriber? Click here to view full article